Alkem appoints Dr Amrut Naik as CEO effective 11 November 2026

External CEO appointedManagement Changes View source PDF Explain this filing

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹5171.00

prior close

₹5190.00

announcement price

After-mkt

timing

Nifty Midcap 150marketpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.3%+2.8% vs sector

On the reaction day the stock moved 2.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.3

15m

-0.3

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4pendingpending-0.3+2.8

Next day

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alkem Laboratories appointed Dr. Amrut Naik as chief executive officer and key managerial personnel, effective 11 November 2026. His contract will continue while he remains employed. He has over 26 years of global pharmaceutical experience across branded medicines, generics, APIs, biologics, vaccines, specialty products and innovation-led portfolios.

Likely market impact

The appointment strengthens Alkem's senior management and may support business growth, although no financial terms were disclosed.